A new test will soon be offered by Rosetta Genomics that will be able to distinguish asbestos-caused malignant pleural mesothelioma from lung cancer. The miRview™meso test is a MicroRNA-based diagnostic test that will allow doctors to rule out the possibility of mesothelioma in those individuals that have been exposed to asbestos-containing materials.

Exposure to asbestos has been known to result in any one of a number of asbestos-related diseases which include not only lung cancer and mesothelioma, (often referred to as asbestos cancer) but asbestosis and other respiratory problems as well. Often because such diseases have a significantly long latency period treatment options for those diagnosed are often very limited. In many cases the diseases are in their advanced stages by the time that they are discovered twenty to sixty years after initial exposure to the dangerous toxin.

Rosetta Genomics’ clinical lab located in Philadelphia, Pennsylvania is expecting to conduct approximately two-thousand of the miRview™meso tests throughout 2009. The company has approximately sixteen million dollars in funds appropriated for the testing that will be conducted at the Philadelphia clinical lab.

According to researchers for the company this is the first test of this type and as Harvey Pass, MD has stated, “Will become an important tool for both oncologists and pathologists in obtaining the right diagnosis in these patients.”

Rosetta Genomics made the announcement regarding the availability of the test early last week.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.